Pfizer (PFE) fundamentals: P/E, valuation, undervalued?
Pfizer · Health Care · ref. ETF XLV · price $28.37
In short — Pfizer trades at 37.3× earnings (P/E), 9.8× forward, with a net margin of 6.8 % and revenue growth of +3 %. Read: High P/E (P/E 37 (above average)).
Is Pfizer stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$28.37+15.7% over range
Oct 14, 25low $23.67 · high $29.02Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 9 analysts
Valuation : High P/E — P/E 37 (above average)
Valuation
37.3
P/E (price/earnings)
9.8
Forward P/E
—
PEG
1.9
Price/book (P/B)
$161.7B
Market cap
0.76
EPS
Profitability & growth
6.8 %
Net margin
+3 %
Revenue growth
—
Earnings growth
$63.5B
Total debt
Pfizer income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $100.3B | $31.4B | 31.3 % |
| 2023 | $58.5B | $2.1B | 3.6 % |
| 2024 | $63.6B | $8.0B | 12.6 % |
| 2025 | $62.6B | $7.8B | 12.4 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Pfizer's P/E and is the stock undervalued? What's a good P/E?
Pfizer's P/E is 37.3 (forward 9.8). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "High P/E".
Is Pfizer profitable?
Pfizer has a net margin of 6.8 % (EPS 0.76). The company is profitable.
Is PFE stock expensive?
Our read: "High P/E" — P/E 37 (above average). Cross-check with growth and sector.
💬 A question about Pfizer? The JPI assistant answers using our backtest data.